- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 55,02 | +0,07 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| GENMAB | 202,80 | +0,70 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2024 | Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,134 | +1,16 % | Arbutus Biopharma Aktie: Portfolioerweiterungen im Fokus | Die Arbutus Biopharma Corporation verzeichnete am 18. Januar 2025 eine leichte Abwärtsbewegung an der Börse. Der Aktienkurs des Biotech-Unternehmens sank um 0,62 Prozent auf 3,20 USD. Die Marktkapitalisierung... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 | - Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) and engaged leading contract research... ► Artikel lesen | |
| VERICEL | 57,00 | +0,88 % | Vericel Corporation: Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets | Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,526 | -0,38 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 1,000 | +1,01 % | MustGrow Biologics Corp.: MustGrow Announces Closing of Private Placement of Units for $2,585,000 | Saskatoon, Saskatchewan--(Newsfile Corp. - January 16, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce the closing of the... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,350 | +1,19 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| AKEBIA | 2,240 | -2,18 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of... ► Artikel lesen | |
| REGENXBIO | 7,450 | -1,32 % | REGENXBIO (NASDAQ:RGNX) Receives "Outperform" Rating from Royal Bank of Canada | ||
| FENNEC PHARMACEUTICALS | 6,050 | +9,01 % | Fennec Pharmaceuticals Inc (NASDAQ:FENC) Sees Large Decrease in Short Interest | ||
| ZEVRA THERAPEUTICS | 7,950 | +1,27 % | Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 | CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,500 | -0,57 % | Dermata Therapeutics: Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari with Daxxify | The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari with Daxxify® to treat primary axillary hyperhidrosis -If successful, the Companies may explore clinical development... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 5,270 | +0,76 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 19,300 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment... ► Artikel lesen |
BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,46 % bei einem Aktienkurs von 0,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.
